(Q37880858)

24 August 2017

1 reference

title

Chronic heart failure: current evidence, challenges to therapy, and future directions (English)

1 reference

24 August 2017

0 references

chronic heart failure

1 reference

Ryan P Morrissey

1

1 reference

24 August 2017

Lawrence Czer

series ordinal

2

1 reference

24 August 2017

Prediman K Shah

series ordinal

3

1 reference

24 August 2017

publication date

1 June 2011

1 reference

American journal of cardiovascular drugs

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

153-171

1 reference

HFSA 2010 Comprehensive Heart Failure Practice Guideline

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Does cardiac resynchronisation therapy improve survival and quality of life in patients with end-stage heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Long-term use of a left ventricular assist device for end-stage heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Advanced heart failure treated with continuous-flow left ventricular assist device.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Vasodilator therapy of cardiac failure: (first of two parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

High-versus low-dose ACE inhibitor therapy in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Beta-blockers in congestive heart failure. A Bayesian meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Haemodynamic effects of nifedipine in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Combination of loop diuretics with thiazide-type diuretics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Healthcare costs of patients with heart failure treated with torasemide or furosemide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Inotropic therapy for heart failure: an evidence-based approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Rationale and design of the enoximone clinical trials program

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Oral levosimendan in patients with severe chronic heart failure --the PERSIST study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Iron deficiency: an ominous sign in patients with systolic chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Thyroid hormone and the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Thyroid replacement therapy and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Growth hormone and testosterone in heart failure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Testosterone treatment for men with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Adverse events associated with testosterone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Gene therapy in the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Phosphodiesterase inhibition in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Chocolate intake and incidence of heart failure: a population-based prospective study of middle-aged and elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Keeping your patient with heart failure safe: a review of potentially dangerous medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Increased mortality after dronedarone therapy for severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Clinical practice. Hypertrophic obstructive cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Depression after coronary artery disease is associated with heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Relationship between depression, BNP levels and ventricular impairment in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Treatment of depression in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Sexual concerns and sexual counseling in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Sexual activity and chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Erectile dysfunction in heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592090-000000000-00000

10.2165/11592090-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1041579575

0 references

1 reference